TheNote
GSK presents new data showing ... Note
GooglePlay AppStore
GSK press releases

GSK presents new data showing promising anti-tumour activity with GSK3359609, an ICOS receptor agonist, in combination with pembrolizumab in head and neck squamous cell carcinoma (HNSCC)

Data presented at ESMO 2019 support phase II/III registrational trial with pembrolizumab in first-line recurrent/metastatic HNSCC.
https://www.gsk.com/en-gb/media/press-releases/gsk-presents-new-data-showing-promising-anti-tumour-activity-with-gsk3359609/ gsk.com
RSS Hunter RSS Hunter • Sep 28, 2019